DaVita
🇺🇸 NYSE:DVA
•
Dec 31, 2024
DaVita Q4 2024 Earnings Report
DaVita reported solid financial growth in Q4 2024, with higher revenue and improved profitability.
Key Takeaways
DaVita Inc. delivered strong Q4 2024 results, with revenue reaching $3.295 billion, a 4.73% increase YoY. Operating margin expanded to 17.2%, reflecting cost efficiencies and higher reimbursement rates. Adjusted EPS was $2.24, while net income rose significantly to $259.33 million.
Revenue grew 4.73% YoY to $3.295 billion.
Operating income increased to $565 million, with a 17.2% margin.
Adjusted EPS of $2.24 reflected improved profitability.
Strong performance in Integrated Kidney Care with 48.2% YoY growth.
DaVita Revenue
DaVita EPS
DaVita Revenue by Segment
DaVita Revenue by Geographic Location
Forward Guidance
DaVita expects continued revenue growth and profitability improvements in 2025, with adjusted EPS guidance between $10.20 and $11.30.
Positive Outlook
- 2025 adjusted operating income guidance of $2.01B - $2.16B.
- Free cash flow expected to be between $1.00B - $1.25B.
- Continued growth in risk-based Integrated Kidney Care segment.
- Strong cost controls and efficiency initiatives improving margins.
- Ongoing share repurchase program supporting EPS growth.
Challenges Ahead
- Declining treatment volume due to lower patient census.
- Increased costs from center closures and restructuring.
- Higher general and administrative expenses impacting profitability.
- Potential reimbursement rate changes affecting revenue.
- Rising labor and insurance costs adding operational pressures.
Revenue & Expenses
Visualization of income flow from segment revenue to net income